Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON 2 25 versus TINDAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON 2 25 versus TINDAL.
ETRAFON 2-25 vs TINDAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of perphenazine (a typical antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks postsynaptic dopamine D2 receptors in the mesolimbic system, also antagonizes alpha-adrenergic, histaminergic, and muscarinic receptors. Amitriptyline inhibits reuptake of serotonin and norepinephrine at the presynaptic neuronal membrane, enhancing serotonergic and noradrenergic neurotransmission.
TINDAL (trimethoprim) inhibits bacterial dihydrofolate reductase (DHFR), preventing the reduction of dihydrofolate to tetrahydrofolate, thereby inhibiting bacterial DNA synthesis.
One tablet (2 mg perphenazine, 25 mg amitriptyline) orally three or four times daily. Maintenance: 2-4 tablets daily.
TINDAL (ticarcillin disodium + clavulanate potassium) 3.1 g (ticarcillin 3 g + clavulanic acid 0.1 g) IV every 4-6 hours. Maximum dose: 18 g ticarcillin/0.6 g clavulanic acid per day.
None Documented
None Documented
Perphenazine: 8-12 hours (terminal); amitriptyline: 15-24 hours (terminal), with nortriptyline active metabolite half-life 18-44 hours. Steady-state achieved in 4-7 days.
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; prolonged in renal impairment.
Renal: approximately 25-50% as metabolites and unchanged drug; biliary/fecal: 10-25% as metabolites; the remainder is extensively metabolized via hepatic pathways.
Primarily renal excretion of unchanged drug (70-80%) and hepatic metabolism (20-30%).
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic